Evaluation of the topical gel and oral administration of Punica Granatum Var Pleniflora on oral mucositis induced by 5-Fluorouracil in golden hamsters.


Journal

BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232

Informations de publication

Date de publication:
07 Jul 2023
Historique:
received: 27 01 2023
accepted: 24 06 2023
medline: 10 7 2023
pubmed: 8 7 2023
entrez: 7 7 2023
Statut: epublish

Résumé

Oral mucositis (OM), an acute inflammation of the oral cavity, is a common complication in patients undergoing invasive myeloblastic chemotherapy or radiation therapy. 5-fluorouracil (5-FU) is one of the most effective therapeutic drugs, but one of the common side effects of 5-FU administration is OM. Unfortunately, no suitable treatment has been found, so far to control its side effects. Studies showed that herbal medicine like Punica granatum var pleniflora (PGP) has medicinal properties such as anti-inflammatory and antibacterial and can be an alternative for the treatment of fungal infection. Accordingly, we decided to investigate the therapeutic effect of PGP in the treatment of OM caused by 5-FU in golden hamsters. Sixty male golden hamsters were divided into six main group. Chemotherapy with 5-FU at dose of 60 mg/kg was performed at a ten-day duration. Then, cheek pouches of the hamsters were scratched with an 18-gauge sterile needle to induce oral mucositis in animals. On the twelfth day, as a day of intensification of OM, treatment with PGP including topical gel with concentrations of 5% and 10% and oral administration of hydro-alcoholic extract with doses of 125 mg/kg and 250 mg/kg for three- and five-day therapeutic duration were separately started. Finally, samples of cheek pouches in hamsters were collected on 14th and 17th days and histopathologic score (HPS), malondialdehyde (MDA), and myeloperoxidase (MPO) levels were assayed. A significant (p < 0.05) decrease in histopathologic score was observed in G It is possible that PGP can play protective role in the healing of tissue damage caused by chemotherapy with 5-FU due to the presence of its natural compounds and antioxidant properties.

Sections du résumé

BACKGROUND BACKGROUND
Oral mucositis (OM), an acute inflammation of the oral cavity, is a common complication in patients undergoing invasive myeloblastic chemotherapy or radiation therapy. 5-fluorouracil (5-FU) is one of the most effective therapeutic drugs, but one of the common side effects of 5-FU administration is OM. Unfortunately, no suitable treatment has been found, so far to control its side effects. Studies showed that herbal medicine like Punica granatum var pleniflora (PGP) has medicinal properties such as anti-inflammatory and antibacterial and can be an alternative for the treatment of fungal infection. Accordingly, we decided to investigate the therapeutic effect of PGP in the treatment of OM caused by 5-FU in golden hamsters.
METHODS METHODS
Sixty male golden hamsters were divided into six main group. Chemotherapy with 5-FU at dose of 60 mg/kg was performed at a ten-day duration. Then, cheek pouches of the hamsters were scratched with an 18-gauge sterile needle to induce oral mucositis in animals. On the twelfth day, as a day of intensification of OM, treatment with PGP including topical gel with concentrations of 5% and 10% and oral administration of hydro-alcoholic extract with doses of 125 mg/kg and 250 mg/kg for three- and five-day therapeutic duration were separately started. Finally, samples of cheek pouches in hamsters were collected on 14th and 17th days and histopathologic score (HPS), malondialdehyde (MDA), and myeloperoxidase (MPO) levels were assayed.
RESULTS RESULTS
A significant (p < 0.05) decrease in histopathologic score was observed in G
CONCLUSIONS CONCLUSIONS
It is possible that PGP can play protective role in the healing of tissue damage caused by chemotherapy with 5-FU due to the presence of its natural compounds and antioxidant properties.

Identifiants

pubmed: 37420236
doi: 10.1186/s12906-023-04053-1
pii: 10.1186/s12906-023-04053-1
pmc: PMC10327340
doi:

Substances chimiques

Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

225

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

Oncotarget. 2021 Oct 26;12(22):2283-2299
pubmed: 34733419
Plants (Basel). 2021 Jan 14;10(1):
pubmed: 33466616
Nanomedicine (Lond). 2014 Aug;9(11):1727-43
pubmed: 25321172
Support Care Cancer. 2022 Sep;30(9):7205-7218
pubmed: 35486227
Oral Dis. 2016 Jan;22(1):39-45
pubmed: 26407909
Support Care Cancer. 2000 Jan;8(1):33-9
pubmed: 10650895
Integr Med Res. 2014 Jun;3(2):83-90
pubmed: 28664082
Expert Opin Drug Deliv. 2016;13(3):349-60
pubmed: 26609868
Cancer Chemother Pharmacol. 2007 Apr;59(5):603-12
pubmed: 16944152
J Dent (Shiraz). 2016 Dec;17(4):334-342
pubmed: 27942549
Biomed Pharmacother. 2022 Sep;153:113256
pubmed: 36076615
Polim Med. 2021 Jul-Dec;51(2):69-75
pubmed: 34783203
Antioxidants (Basel). 2020 Aug 03;9(8):
pubmed: 32756489
J Oral Pathol Med. 2017 Oct;46(9):725-730
pubmed: 27977896
J Support Oncol. 2004 Nov-Dec;2(6 Suppl 3):3-8
pubmed: 15605918
Altern Med Rev. 2008 Jun;13(2):128-44
pubmed: 18590349
Adv Drug Deliv Rev. 2007 Jul 10;59(6):427-43
pubmed: 17544165
J Wound Care. 2021 Aug 02;30(8):618-625
pubmed: 34382850
Food Chem. 2021 Aug 1;352:129396
pubmed: 33652195
J Ultrasound Med. 2023 May;42(5):1065-1073
pubmed: 36342110
Pharm Biol. 2021 Dec;59(1):1-10
pubmed: 33378625
Eur J Oral Sci. 2005 Jun;113(3):210-7
pubmed: 15953245
Anticancer Agents Med Chem. 2013 Oct;13(8):1149-61
pubmed: 23094914
Curr Treat Options Oncol. 2003 Feb;4(1):27-41
pubmed: 12525277
Int J Oral Maxillofac Surg. 2014 Oct;43(10):1286-92
pubmed: 24948410
J Clin Exp Dent. 2015 Apr 01;7(2):e304-9
pubmed: 26155351
Dis Mon. 2022 May;68(5):101300
pubmed: 34758917
J Evid Based Complementary Altern Med. 2017 Jan;22(1):59-67
pubmed: 26922436
Environ Sci Pollut Res Int. 2017 Nov;24(31):24447-24453
pubmed: 28895047
Braz Dent J. 2020 Jun;31(3):310-318
pubmed: 32667525
Curr Drug Discov Technol. 2021;18(2):225-234
pubmed: 32013832
Support Care Cancer. 2014 Jun;22(6):1557-62
pubmed: 24442926
BMC Complement Altern Med. 2015 Oct 15;15:366
pubmed: 26470879
Foods. 2022 Aug 26;11(17):
pubmed: 36076774
Eur J Obstet Gynecol Reprod Biol. 2020 Mar;246:113-116
pubmed: 32004879
Indian J Otolaryngol Head Neck Surg. 2019 Oct;71(Suppl 1):318-320
pubmed: 31741979
Acta Pol Pharm. 2010 Jan-Feb;67(1):107-10
pubmed: 20210088
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
Biochem Mol Biol Int. 1999 Jun;47(6):979-89
pubmed: 10410244
Planta Med. 2016 Nov;82(17):1463-1467
pubmed: 27352385
Atherosclerosis. 1998 Apr;137 Suppl:S45-50
pubmed: 9694541
Antibiotics (Basel). 2022 Apr 27;11(5):
pubmed: 35625228
J Clin Oncol. 2001 Apr 15;19(8):2201-5
pubmed: 11304772
Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):437-43
pubmed: 2326035
Environ Sci Pollut Res Int. 2021 Feb;28(6):7134-7150
pubmed: 33029776
J Support Oncol. 2007 May;5(5):231-5
pubmed: 17564153
Cancer. 2007 Mar 1;109(5):820-31
pubmed: 17236223
Eur J Pharm Biopharm. 2017 Mar;112:30-37
pubmed: 27867111
J Agric Food Chem. 2002 Aug 14;50(17):4791-5
pubmed: 12166961
Phys Sportsmed. 2013 May;41(2):64-74
pubmed: 23703519
Molecules. 2022 Jul 20;27(14):
pubmed: 35889496
J Ethnopharmacol. 2003 Dec;89(2-3):295-300
pubmed: 14611895

Auteurs

Seyede Pegah Hamidi (SP)

Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran.

Omid Koohi-Hosseinabadi (O)

Central Research Laboratory, Shiraz University of Medical Sciences, Shiraz, Iran.

Sepideh Khaksar (S)

Department of Plant Sciences, Faculty of Biological Sciences, Alzahra University, Tehran, Iran.

Ali Ghanbariasad (A)

Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran.
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.

Amir Reza Dehghanian (AR)

Surgical and Clinical Pathology, Shiraz University of Medical Sciences, Shiraz, Iran.

Azizallah Dehghan (A)

Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.

Zahra Haddadi (Z)

Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran.

Roxana Gorgin (R)

Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran.

Mojtaba Farjam (M)

Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran. farjam.phd@gmail.com.

Hiva Alipanah (H)

Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran. alipanah.hiwa@yahoo.com.
Department of Physiology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran. alipanah.hiwa@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH